Dupilumab is an interleukin (IL)-4 receptor α antagonist that blocks both the IL-4 and IL-13 pathways and has demonstrated efficacy in atopic dermatitis (AD) treatment (5). This evidence concerns the gene IL4 and Alzheimer disease.